This study looked at 660 patients who underwent radical surgery for esophageal cancer. Researchers examined blood markers called the inflammation–immunity–nutrition score and the red cell distribution width-to-lymphocyte ratio. They compared these markers against the standard AJCC staging system used to describe cancer spread.
The results showed that the new blood markers were independent predictors of survival. A model using these markers showed better ability to distinguish between patients with different outcomes than the standard system. Additional tests confirmed that using these markers provided a net benefit for risk assessment.
The study suggests these tools could support individualized risk stratification and perioperative optimization. They might also help inform patient selection for immunotherapy. However, the authors note that external multicenter validation is warranted. Because this was a retrospective study, the findings need confirmation in other settings before they are widely adopted.